ESTA Stock Analysis: Establishment Labs Holdings | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 1.997m USD | 12M Return: -0.7% | VGG312491084 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.5M
Qual. Beats: 0
Rev. Trend: 93.0%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.3 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
Establishment Labs Holdings Inc. (NASDAQ: ESTA) is a medical technology company that develops, manufactures, and markets medical devices focused on breast aesthetic and reconstructive plastic surgery. Its flagship product line is the Motiva brand of silicone gel-filled breast implants, and it also offers breast tissue expanders used in reconstruction procedures. The company distributes its products to physicians, hospitals, and clinics through a combination of third-party distributors and a direct sales force, with commercial reach spanning Europe, the Middle East, Africa, Latin America, Asia, and the United States. Established in 2004 and headquartered in Austin, Texas, the company has been publicly traded since its 2018 IPO and is classified within the Health Care Supplies sub-industry.
The breast implant and aesthetic medical device market is characterized by stringent regulatory oversight, with products typically requiring premarket approvals such as FDA clearance in the U.S. and CE marking in Europe, creating high barriers to entry. Companies in this space generally rely on surgeon training, clinical evidence, and long-term safety data as key competitive differentiators, and the broader category benefits from rising global demand for both cosmetic and reconstructive procedures.
- Motiva FDA approval unlocks US breast implant market entry
- International revenue growth offsets elevated US launch spending and operating losses
- Competition from AbbVie and Sientra pressures market share gains
| Net Income: -38.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.06 > 0.02 and ΔFCF/TA 16.74 > 1.0 |
| NWC/Revenue: 69.73% < 20% (prev 87.77%; Δ -18.04% < -1%) |
| CFO/TA -0.04 > 3% & CFO -13.8m > Net Income -38.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.57 > 1.5 & < 3 |
| Outstanding Shares: last quarter (30.4m) vs 12m ago 2.73% < -2% |
| Gross Margin: 70.18% > 18% (prev 68.74%; Δ 1.44% > 0.5%) |
| Asset Turnover: 75.68% > 50% (prev 56.35%; Δ 19.33% > 0%) |
| Interest Coverage Ratio: -0.62 > 6 (EBIT TTM -17.4m / Interest Expense TTM 28.2m) |
| A: 0.51 (Total Current Assets 255.7m - Total Current Liabilities 71.6m) / Total Assets 358.9m |
| B: -1.48 (Retained Earnings -531.6m / Total Assets 358.9m) |
| C: -0.05 (EBIT TTM -17.4m / Avg Total Assets 348.9m) |
| D: 0.05 (Book Value of Equity 15.6m / Total Liabilities 343.3m) |
| Altman-Z'' = -1.75 = D |
| DSRI: 0.79 (Receivables 77.9m/71.4m, Revenue 264.0m/191.0m) |
| GMI: 0.98 (GM 68.74% / 70.18%) |
| AQI: 1.35 (AQ_t 0.07 / AQ_t-1 0.05) |
| SGI: 1.38 (Revenue 264.0m / 191.0m) |
| TATA: -0.07 (NI -38.5m - CFO -13.8m) / TA 358.9m) |
| Beneish M = -2.74 (Cap -4..+1) = A |
As of November 11, 2026, the stock is trading at USD 67.23 with a total of 390,829 shares traded. Over the past week, the price has changed by +9.50%, over one month by +9.09%, over three months by -10.43% and over the past year by -0.68%.
Current recommended Stop Loss: 59.30 (which is 11.8% or 1.8 ATR below the current price).
Establishment Labs Holdings has received a consensus analysts rating of 4.80. Therefore, it is recommended to buy ESTA.
- StrongBuy: 8
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 98 | 45.8% |
P/E Forward = 217.3913
P/S = 7.5648
P/B = 128.0828
Revenue TTM = 264.0m USD
EBIT TTM = -17.4m USD
EBITDA TTM = -6.88m USD
Long Term Debt = 247.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 14.1m USD (from shortTermDebt, last fiscal year)
Debt = 271.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.97m
Net Debt = 195.7m USD (calculated: Debt 271.5m - CCE 75.8m)
Enterprise Value = 2.19b USD (2.00b + Debt 271.5m - CCE 75.8m)
Interest Coverage Ratio = -0.62 (Ebit TTM -17.4m / Interest Expense TTM 28.2m)
EV/FCF = -99.51x (Enterprise Value 2.19b / FCF TTM -22.0m)
FCF Yield = -1.00% (FCF TTM -22.0m / Enterprise Value 2.19b)
FCF Margin = -8.35% (FCF TTM -22.0m / Revenue TTM 264.0m)
Net Margin = -14.56% (Net Income TTM -38.5m / Revenue TTM 264.0m)
Gross Margin = 70.18% ((Revenue TTM 264.0m - Cost of Revenue TTM 78.7m) / Revenue TTM)
Gross Margin QoQ = 69.05% (prev 70.64%)
Tobins Q-Ratio = 6.11 (Enterprise Value 2.19b / Total Assets 358.9m)
Interest Expense / Debt = 10.38% (Interest Expense 28.2m / Debt 271.5m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -13.7m (EBIT -17.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.57 (Total Current Assets 255.7m / Total Current Liabilities 71.6m)
Debt / Equity = 17.41 (Debt 271.5m / totalStockholderEquity, last quarter 15.6m)
Debt / EBITDA = -28.45 (negative EBITDA) (Net Debt 195.7m / EBITDA -6.88m)
Debt / FCF = -8.88 (negative FCF - burning cash) (Net Debt 195.7m / FCF TTM -22.0m)
Total Stockholder Equity = 18.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -11.02% (Net Income -38.5m / Total Assets 358.9m)
RoE = -203.6% (Net Income TTM -38.5m / Total Stockholder Equity 18.9m)
RoCE = -6.51% (EBIT -17.4m / Capital Employed (Equity 18.9m + L.T.Debt 247.5m))
RoIC = -4.76% (negative operating profit) (NOPAT -13.7m / Invested Capital 288.2m)
WACC = 8.93% (E(2.00b)/V(2.27b) * Re(9.03%) + D(271.5m)/V(2.27b) * Rd(10.38%) * (1-Tc(0.21)))
Discount Rate = 9.03% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 92.29 | Cagr: 3.93%
[DCF] Fair Price = unknown (Cash Flow -22.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.36 | # QB: 0
Revenue Correlation: 93.02 | Revenue CAGR: 22.05% | SUE: 4.0 | # QB: 3
EPS current Quarter (2027-03-31): EPS=-0.29 | Chg30d=-20.83% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.34 | Chg30d=-21.82% | Revisions=-25% | GrowthEPS=+23.1% | GrowthRev=+30.2%
EPS next Year (2027-12-31): EPS=-0.22 | Chg30d=-462.50% | Revisions=+0% | GrowthEPS=+83.8% | GrowthRev=+24.8%
[Analyst] Revisions Ratio: -25% (up=0, down=1)